Art

J-GLOBAL ID：201502212771882363   Reference number：15A1014189

Reactivation of resolved infection with the hepatitis B virus immune escape mutant G145R during dasatinib treatment for chronic myeloid leukemia

慢性骨髄性白血病に対するダサチニブ治療中のB型肝炎ウイルスの免疫回避変異体G145Rによる消失感染再活性化

Author (7)： ANDO Toshihiko (Saga Univ., Div. of Hematology, Respiratory Medicine and Oncology, Dep. of Internal Medicine, Fac. of Medicine ...) ,  KOJIMA Kensuke (Saga Univ., Div. of Hematology, Respiratory Medicine and Oncology, Dep. of Internal Medicine, Fac. of Medicine ...) ,  ISODA Hiroshi (Saga Univ., Div. of Hepatology, Diabetes, Metabolism and Endocrinology, Dep. of Internal Medicine, Fac. of Medicine ...) ,  EGUCHI Yuichiro (Div. of Hepatology, Saga Medical School, Liver Center, Saga, JPN) ,  HONDA Takashi (Dep. of Gastroenterology and Hepatology Nagoya Univ. School of Medicine, Nagoya, JPN) ,  ISHIGAMI Masatoshi (Dep. of Gastroenterology and Hepatology Nagoya Univ. School of Medicine, Nagoya, JPN) ,  KIMURA Shinya (Saga Univ., Div. of Hematology, Respiratory Medicine and Oncology, Dep. of Internal Medicine, Fac. of Medicine ...)
Material： International Journal of Hematology  (Int J Hematol)
Volume： 102  Issue： 3  Page： 379-382  Publication year： Sep. 2015 
JST Material Number： F0888A  ISSN： 0925-5710  CODEN： IJHEEY  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： *chronic myeloid leukemia ,...
Semi thesaurus term： *hepatitis B virus infection ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=15A1014189&from=J-GLOBAL&jstjournalNo=F0888A") }}

JST classification (3)： Clinical oncology in general  (GE03010Y) ,  Blood cell tumors(=neoplasms)  (GK04000M) ,  Infectious diseases,parasitics diseases in general.  (GD01010H)

Substance index (1)： Dasatinib

Reference (28)：

• Hwang JP, Lok AS. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol. 2014;11:209-19.
• Fukushima N, Mizuta T, Tanaka M, Yokoo M, Ide M, Hisatomi T, et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol. 2009;20:2013-7.
• Skrabs C, Müller C, Agis H, Mannhalter C, Jäger U. Treatment of HBV-carrying lymphoma patients with Rituximab and CHOP: a diagnostic and therapeutic challenge. Leukemia. 2002;16:1884-6.
• Yeo W, Chan TC, Leung NW, Lam WY, Mo FK, Chu MT, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605-11.
• Coppola N, Tonziello G, Pisaturo M, Messina V, Guastafierro S, Fiore M, et al. Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. J Med Virol. 2011;83:1909-16.

Terms in the title (7)： 慢性骨髄性白血病 ,  ダサチニブ ,  治療 ,  B型肝炎ウイルス ,  免疫回避 ,  変異体 ,  感染再活性